What is Caldera Therapeutics?
Caldera Therapeutics operates as a clinical-stage biotechnology enterprise dedicated to the discovery and development of novel therapeutic candidates. Its flagship asset, CLD-423, represents a first-in-class bispecific antibody designed to modulate the IL-23p19 and TL1A pathways. By focusing on these clinically validated targets, the company aims to redefine the standard of care for patients suffering from chronic inflammatory and immunologic conditions. The organization is supported by a leadership team with extensive experience in drug discovery and a proven history of navigating the biotech lifecycle from inception to successful exit, ensuring a disciplined approach to clinical development.
How much funding has Caldera Therapeutics raised?
Caldera Therapeutics has raised a total of $112.5M across 2 funding rounds:
Other Financing Round
$37.5M
Series A
$75M
Other Financing Round (2026): $37.5M with participation from Wellington Management, Omega Alpha Spac, and Janus Henderson Investors
Series A (2026): $75M led by Atlas Venture and venBio Partners
Key Investors in Caldera Therapeutics
Atlas Venture
A pioneering early-stage venture capital firm focused on creating and building breakthrough biotechnology companies that translate cutting-edge science into life-changing medicines.
venBio Partners
A life sciences investment firm that partners with industry leaders to develop innovative medicines and technologies, focusing on novel therapeutics for unmet medical needs.
Wellington Management
A global, independent investment management firm providing institutional clients with research-driven portfolio management and tailored investment solutions across diverse asset classes.
What's next for Caldera Therapeutics?
With the recent influx of capital, Caldera Therapeutics is poised to transition its lead programs through critical clinical milestones. The strategic focus will likely center on the rigorous evaluation of CLD-423, leveraging the expertise of its high-profile investor syndicate to optimize trial design and regulatory strategy. As the company scales its operations, the emphasis will remain on maintaining a lean, high-impact development model that prioritizes data-driven decision-making. Future growth will be defined by the ability to demonstrate superior efficacy in IBD patient populations, potentially positioning the company as a prime candidate for long-term strategic partnerships or acquisition within the broader pharmaceutical ecosystem.
See full Caldera Therapeutics company page
